Not sure if TLT can attack this gene AstraZeneca and Daiichi Sankyo on Friday revealed new study results supporting their revised approval plans for the closely watched cancer drug datopotamab deruxtecan, or dato-dxd. A pooled analysis from two clinical trials showed dato-dxd kept tumors in check for a median of about six months in people whose non-small cell lung tumors were driven to growth by mutations in the EGFR gene. Among 117 people, median survival was 15.6 months, according to a statement. The findings underpin an accelerated approval filing the partners submitted last month in EGFR-mutated lung cancer — a much narrower request than they’d originally anticipated.
If TLT can cure this we are headed to infinity and beyond.